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Nanotechnology is providing a new therapeutic paradigm by enhancing drug efficacy and preventing 
side-effects. Edelfosine is a synthetic ether lipid analogue of platelet activating factor with high antitumor 
activity. The encapsulation of this potent antitumor drug in lipid nanoparticles increases its oral 
bioavailability; moreover, it prevents the hemolytic and gastrointestinal side-effects of the free drug. The 
literature points towards lymphatic absorption of lipid nanoparticles after oral administration, and 
previous in vitro and in vivo studies stress the protection against toxicity that these nanosystems provide. 
The present study is intended to assess the permeability of lipid nanoparticles across the intestinal barrier. 
Caco-2 monoculture and Caco-2/Raji co-culture were used as in vitro models of enterocytes and 
Microfold cells respectively. Results showed that free drug is internalized and possibly metabolized in 
enterocytes. These results do not correlate with those observed in vivo when edelfosine-lipid 
nanoparticles were administered orally in mice, which suggests that the microfold model is not a good 
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 1. Introduction 
Edelfosine (ET) is a synthetic ether lipid analogue of platelet activating factor (PAF) with proved in vitro 
and in vivo antitumor activity [1]. However, it presents some drawbacks such as hemolysis after 
intravenous administration and gastrointestinal toxicity and poor bioavailability after oral administration 
[2]. These drawbacks can be overcome through nanotechnology [3]. Lipid nanoparticles (LN) prevent ET 
toxicity [4] and improve its oral bioavailability [2]. Moreover, they can be formulated by an organic 
solvent free method using biodegradable lipids [5]. Due to their physicochemical characteristics, LN 
containing ET (ET-LN) can be administered orally, intravenously and intraperitoneally [3]. Bearing in 
mind the importance of oncological patient well-being, the possibility of administering therapy by oral 
route is a challenge. Several in vivo studies report accumulation of the drug in the lymph nodes, endorsing 
lymphatic intestinal absorption after LN oral administration [3]. In order to obtain further insight into the 
evaluation of drug absorption in the gastrointestinal tract, several in vitro models have been developed 
since the 1980s [6]. Among all these models, Caco-2 monoculture is one of the most commonly used due 
to its ability to simulate the intestinal epithelium. The human epithelial colorectal adenocarcinoma cell 
line Caco-2 differentiates to enterocyte-like cells under specific culture conditions [6]. In addition, the 
hypothesis of lymphatic oral absorption of LN has promoted the development of intestinal in vitro models 
that simulate microfold cells (M cells) of Peyer`s patches in the intestinal follicle-associated epithelium 
(FAE). M cells specialize in transporting soluble macromolecules, small particles and entire 
microorganisms from the intestinal lumen to the immune system. These cells have unique morphological 
features including the presence of a reduced glycocalyx, irregular brush border and reduced microvilli [7]. 
Previous authors have developed numerous strategies to obtain M-cell like in vitro models [8-12]. This 
work includes the development of an in vitro model of M cells based on the strategy of co-cultivating 
Caco-2 cells with Raji cells (B lymphocytes derived from Burkitt cell lymhoma) [9]. ET and ET-LN 
transport across mono and co-culture models are evaluated in the present study.  
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2. Material and methods 
2.1. Materials 
ET was purchased from APOINTECH (Salamanca, Spain). Precirol® ATO 5 was a gift from Gattefossé 
(France). Tween® 80 was purchased from Roig Pharma (Barcelona, Spain). Chloroform was obtained 
from Panreac (Madrid, Spain), formic acid 99% for mass spectroscopy was obtained from Fluka 
(Barcelona, Spain), and methanol was purchased from Merck (Barcelona, Spain). All solvents employed 
for the chromatographic analysis were of analytical grade; all other chemicals were reagent grade and 
used without further purification. Amicon Ultra-15 10,000 MWCO centrifugal filter devices and Millicell 
Cell Culture Inserts were purchased from Millipore (Cork, Ireland). RPMI 1640 and MEM cell culture 
media, Heat-inactivated Fetal Bovine Serum (FBS), Glutamax, MEM Non-Essential Amino Acids, 
Penicillin/Streptomycin antibiotics, ZO-1 Monoclonal Antibody, Villin-1 Polyclonal Antibody, Alexa 
Fluor®594 Goat Anti-Rabbit IgG (H+L), Topro-3 Iodide and CellTrace CFSE Cell Proliferation Kit were 
purchased from Life Technologies, (Barcelona, Spain). DAPI was obtained from Invitrogen (Madrid, 
Spain). Fluorescence mounting medium was obtained from Dako (Barcelona, Spain). Rhodamine 123 and 
fluorescein sodium were obtained by Sigma Aldrich Química S.A. (Madrid, Spain). M-PER Mammalian 
Protein Extraction Reagent and Silicone tubing were purchased from Thermo Fisher Scientific (Madrid, 
Spain). 
2.2. Preparation and characterization of lipid nanopartciles 
LN were prepared by the hot homogenization method consisting of high shear homogenization and 
ultrasonication [13]. ET (30 mg) and Precirol® (300 mg) were melted at approximately 5ºC above the 
melting point of the lipid (60ºC). A 2% Tween® 80 aqueous solution (10 mL) previously heated at the 
same temperature was added and dispersed in the molten lipid with the help of a Microson™ ultrasonic 
cell disruptor (NY, USA) for 1 min at an effective power of 10W. The preformed emulsion was then 
homogenized with an Ultraturrax® (IKA-Werke, Germany) for 1 min at 24,000 rpm and sonicated again 
with a Microson™ ultrasonic cell disruptor (NY, USA) for 1 min at 10W. The emulsion was removed 
from heat and placed in an ice bath to obtain LN by lipid solidification. Then, the LN suspension was 
centrifuged using Amicon® Ultra-15 10,000 MWCO filters at 4500 × g for 30 min and washed twice 
with distilled water. Afterwards, 150 % (w/w of lipid weight) trehalose was added as cryoprotectant agent 
to the LN suspension, which was then kept at -80ºC and freeze-dried to obtain a nanoparticulate powder. 
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Particle size and polydispersity index (PDI) were evaluated by photon correlation spectroscopy (PCS) 
using a Zetasizer Nano (Malvern Instruments, UK). The measurements were carried out three times. 
Surface charge was measured using the same Zetasizer Nano equipment combined with laser Doppler 
velocimetry. For the ET loading determination, 5 mg of nanoparticles were dissolved in 1 ml of 
chloroform and mixed with 4 ml of methanol. The mixture was vortexed for 1 min and then centrifuged at 
20,000 × g for 10 min. The supernatant was analyzed by a previously validated ultra-high-performance 
liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) method [14]. 
ET-LN morphology was evaluated by transmission electron microscopy (TEM). Images were taken on a 
FEI Tecnai T20 microscope at INA-LMA(Zaragoza). To prepare ET-LN samples for TEM observation, 
lyophilized NPs were dispersed in milli-Q water. After 30 s in an ultrasonic bath, a drop of this 
suspension was applied to a copper grid (200 mesh) coated with carbon film, and allowed to dry in air. 
The microscope was operated at 80 kV to preserve the ET-LN morphology and diminish radiation 
damage. 
2.3. Cell culture 
Caco-2 cells were culture in MEM supplemented with 20% (v/v) fetal bovine serum, 1% v/v non-
essential aminoacids and 1% (v/v) Glutamax at 37ºC under a 5% CO2 water saturated atmosphere. Cells 
were harvested with trypsin/EDTA every 3-4 days and subcultured at 12 x 103 cells/cm2. Raji cells were 
cultured at 0.5 x 106 cells/ml in RPMI supplemented with 20% (v/v) fetal bovine serum, and 1% (v/v) 
penicillin and streptomycin, at 37ºC in a humid atmosphere with 5% CO2. Cells were split 1:3-1:5 every 
3-4 days.  
2.4. Enterocyte and M-cell like: in vitro models of gastrointestinal barrier 
2.4.1. Development 
In vitro models were developed following a previous experiment by des Rieux et al. [9]. The human 
colon adenocarcinoma cell line Caco-2 cells were seeded at a density of 9 x 104 cells on the apical 
chamber of Transwell inserts (3-mm pore PET Transwell filters; 12-well) in MEM supplemented with 
20% (v/v) fetal bovine serum, 1% v/v non-essential aminoacids, 1% (v/v) Glutamax and 1% penicillin 
and streptomycin. Cultures were maintained at 37ºC, 5% CO2 for up to 21 days. The medium was 
replaced every 2-3 days (0.5 ml in the apical compartment and 1.5 ml in the basolateral compartment). In 
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case of the M-cell in vitro model, inserts were inverted after 14 days of culture and a piece of silicon 
(12.8 mm diameter) was placed on the basolateral side of each insert. The silicon piece was filled with a 
suspension of 5 x 105 Raji cells in 1 ml of supplemented MEM. Co-culture was maintained for 4 days. 
Afterwards, Raji cells and silicon tubes were removed and inserts were placed in their original 
orientation. Transport experiments in both models were performed after 21 days of Caco-2 seeding.  
2.4.2. Assessment of cell monolayer integrity 
Cell monolayer integrity was assessed in both models by measurement of trans-epithelial electrical 
resistance (TEER) [15]. Prior to measuring TEER, culture media was replaced by MEM without 
supplements. Inserts were placed at room temperature for 15 minutes and TEER was measured with a 
Millicell ERS-2 Voltohmmeter (Merck Millipore, Germany). The resistance is expressed as Ω/cm2. Cell 
monolayer confluence was analyzed weekly. TEER measurement was also used to assess cell monolayer 
integrity during permeation experiments. 
2.4.3. Characterization of the in vitro intestinal models 
2.4.3.1. Inmunofluorescence 
After 21 days of culture, cell monolayers were washed carefully with PBS, fixed with 4% 
paraformaldehyde (w/v) and permeabilized with Triton X-100 0.5 % (v/v). Monolayers were blocked 
with a 1% BSA solution in TBS. Then cells were incubated with Anti-ZO-1 Alexa Fluor 488 (1:100) and 
Anti-villin (1:100) antibodies in TBS 1%BSA o.n. Later, cells labelled with Villin antibody were 
incubated with Alexa Fluor®594 Goat Anti-Rabbit IgG (H+L) (1:500). Samples were stained with Topro-
3 Iodide or Dapi and visualized under fluorescence and confocal microscopy.  
2.4.3.2. Carboxyfluorescein succinimidyl ester (CFSE) labeling 
Raji cells were incubated with CellTrace CFSE for 15 minutes at 37 ºC (10 µM for flow cytometry and 25 
µM for fluorescence microscopy). Afterwards, cells were incubated in culture media for 30 minutes and 
washed twice with PBS. Three days later, Caco-2 monolayers were co-cultured with the stained Raji cells 
as described above (section 2.4.1). After 21 days, cells monolayers were observed under fluorescence and 
confocal microscopy. Cells were fixed with 4% paraformaldehyde and nuclei were stained with Topro-3 
Iodide or Dapi. In addition, the presence of Raji cells in the culture was quantified by flow cytometry.  
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2.4.4. Transport studies 
TEER was measured before and after the experiments. Only cell monolayers with TEER values over 280 
Ω/cm2 were used. All transport studies were conducted under agitation at 37ºC in transport medium 
(MEM without supplements). Total experiment volumes were 0.5 ml in the apical compartment and 0.6 
ml in the basolateral compartment. The different treatments were added to the donor compartments: Free 
ET (ET) and LN containing ET (ET-LN) at a final dose equivalent to 30 µg/ml of free drug. ET transport 
was studied from the apical compartment to the basolateral compartment (A→B) and vice versa (B→A). 
Fluorescein and rhodamine 123 were used as control substances in the transport experiments. Low 
permeable substance fluorescein free acid was added to the apical compartment at a final concentration of 
100 µg/ml. The p-glycoprotein substrate rhodamine 123 was added to the apical compartment (A→B) 
and to the basolateral compartment (B→A) at a concentration of 5 µg/ml. The experiment lasted 2 hours 
and donor samples were collected at the beginning and at the end of the experiment. Samples were 
analyzed using UHPLC-MS/MS [14] (ET and ET-LN) and fluorescence spectrometry (fluorescein and 
rhodamine). The permeability (apparent permeability coefficient; Papp) was calculated according to the 
following equation [16]: 
Papp= dQ/dt*1/A*C0 [cm/s] 
‘dQ/dt’ is the rate of appearance of drugs on the acceptor compartment (µmol/s); C0 is the initial drug 
concentration on the donor side (mM); ‘A’ is the surface area of the monolayer (cm2).  
2.5. Statistical analysis 
Data analysis and graphic presentations were done using Prism version 5.00 software for Windows 
(GraphPad Software, San Diego, CA). Data are presented as a mean of three or more independent 
experiments, with error bars indicating the standard deviation. Data was analysed using a two-way 
ANOVA statistical test. The statistical significance level was defined as a P value of <0.05.  
3. Results and discussion 
3.1. Lipid nanoparticle formulation 
The hot homogenization method consisting of high shear homogenization and ultrasonication provided 
LN with a size of 127.89 ± 9.95 nm suitable for oral, intravenous and intraperitoneal administration [3] 
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and low polidispersity index (0.24 ±0.01). LN charge was negative and enough to maintain formulation 
stability (-28.42 ± 1.39 mV). This method of LN formulation has been previously developed and used by 
our research group [13, 17, 18]. The formulation used in this study was slightly modified in order to 
increase drug loading capacity. ET-LN loading was 22.677 ± 2.262 µg ET/mg formulation. In comparison 
to LN prepared in the above-mentioned previous studies, increasing the amount of drug that was initially 
added to the nanoparticles (from 15 to 30 mg) allowed us to obtain a higher loading capacity (from 13 µg 
ET/mg formulation to 22.677 µg ET/mg of formulation). Despite the increase in drug loading capacity, 
ET-LN maintained their homogeneous morphology and round shape as is shown in TEM images (Fig. 1).  
 
Figure 1. TEM images of LN containing edelfosine at different magnifications. ET-LN nanoparticles are not aggregated, 
which is in agreement with the polydispersity index obtained by PCS characterization.  
3.2. Transport experiments 
Several adapted in vitro models based on colorectal adenocarcinoma Caco-2 cells have been developed in 
the last decade to test drug permeability across the intestinal barrier [8, 9, 16, 19]. Among all these 
models, Caco-2 monoculture and co-culture of Caco-2 cells with Burkitt lymphoma B cells (Raji cells) 
are being widely used to simulate enterocytes and intestinal M cells respectively. As many researchers 
have reported significant accumulation of LN in the lymphatic system after oral administration [3], M-cell 
in vitro models have been developed in order to assess the absorption of these nano-systems by this route 
and compare it with the absorption by enterocytes (mono-culture of Caco-2 cells).  
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3.2.1. In vitro models of intestinal barrier: characterization 
3.2.1.1. Cell monolayer integrity 
Caco-2 monoculture and Caco-2/Raji co-culture presented similar TEER values after 21 days of culture 
(Fig. 2). As previously described, TEER values decreased after the co-culture with Raji cells for four days 
[9]. However, our results showed that, after removing Raji cells from the culture, TEER values recovered 
and achieved the monoculture values at day 21 (Fig. 2). Caco-2 monoculture and Caco-2/Raji co-culture 
showed TEER values of 480.2 ± 11.56 Ω/cm2 and 502.8 ± 23.50 Ω/cm2 respectively with no statistically 
significant differences between them. All monolayers reached TEER values above 200 Ω/cm2 at the time 
of the transport experiment, indicating the formation of a cell monolayer with maintenance of tight 
junction integrity [16].  
 
Figure 2. TEER values of Caco-2 monoculture and Caco-2/Raji co-culture after 21 days of incubation (Ω/cm2). Monoculture 
of Caco-2 and co-culture with Raji cells did not show differences in TEER values.  
3.2.1.2. Immunofluorescence characterization 
 The formation of a monolayer containing cells phenotypically similar to enterocytes and M cells was 
monitored by immunofluorescence. Tight junctions were labeled with ZO-1 antibody [20]. ZO-1 is a 
protein that is present in the cytoplasmic membrane of cells with tight intercellular junctions. Both 
intestinal models showed the presence of this protein (Fig. 3). However, Caco-2 monoculture presented a 
more homogenous and structured monolayer architecture than Caco-2/Raji co-culture, indicating the 
formation of M-cells (Fig. 3).  
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 Figure 3. Confocal images of Caco-2 monoculture (left) and Caco-2/Raji co-culture (right) stained with ZO-1 antibody; 
x63/1.4. 
Presence of villin, a component of brush border assembly, was also assessed in both cultures. M cells are 
characterized by an irregular brush border and reduced microvilli to facilitate contact with particles and 
microorganisms [7].  
 
Figure 4. Lateral (upper figures) and frontal (lower figures) confocal images of Caco-2 monoculture (left) and Caco-2/Raji 
co-culture (right) stained with Villin antibody (red) and Topro-3 Iodide (blue); x63/1.4. Caco-2 monoculture showed a 
homogeneous layer of villin on the cell surface whereas it was partially distributed in the cell surface of the co-culture model 
(arrows indicate the lack of villin between cells). 
Conversely, villin is present in M cells but its distribution is different, being located mainly in the 
cytoplasmic region [11, 21]. Such expression patterns were reproduced in our experiments (Fig. 4). Fig. 4 
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shows that Caco-2 monocultures presented a homogenous layer of villin on the surface of the cells, 
indicating the development of a brush border typically present in enterocytes. Villin was also visible in 
Caco-2/Raji co-cultures but with a different distribution pattern; in this culture, some cells expressed 
villin in their surface but the protein did not cover the cell monolayer. The imperfect layer of villin 
indicates the differentiation of some Caco-2 cells into M-like cells with their typical reduced brush 
border. 
3.2.1.3. Localization and quantification of Raji cells in Caco-2/Raji co-culture (CFSE labeling) 
In order to localize Raji cells, we stained them with carboxyfluorescein diacetate succinimidyl ester 
(CFSE). This reagent passively diffuses into cells and turns into a fluorescent compound that is retained 
in the cell [22]. The developed model of co-culture is based on the direct contact of Raji cells with Caco-2 
cells. At day 14, inserts were inverted and Raji cells were placed in the basolateral side of the membrane. 
Most authors support the need for direct contact between both cell lines in order to obtain a more reliable 
M-cell model [9, 11]. In the inverted culture model, Raji cells are expected to migrate through the pores 
of the insert membrane and, therefore, to be incorporated into the Caco-2 cell monolayer. Presence of Raji 
cells within the monolayer was visualized by fluorescence microscopy and quantified by flow cytometry. 
The percentage of Raji cells in the culture assessed with flow cytometry was about 27 % of all cells; these 
data were consistent with the results published by Rieux et al. [9], who obtained a percentage between 17 
and 30% of total number of cells. Confocal images showed presence of CFSE labeled cells below the 
inserts (Fig. 5). Raji cells were not detected within the monolayer by fluorescence microscopy and the 
total proportion of fluorescent cells observable by fluorescence microscopy appeared to be lower than 
30%. This discrepancy might be explained due to the higher sensitivity of flow cytometry technique. 
Besides, Raji cells integrated into the cell monolayer might display lower fluorescence intensity, only 
detectable by flow cytometry. In conclusion, enterocyte and M-cell like in vitro culture models were 
successfully developed in our laboratory [9].  
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 Figure 5. Lateral and frontal confocal images (upper and lower left) and fluorescence microscopy image (right) of Caco-
2/Raji co-culture. Tight junctions are stained with ZO-1 antibody (green) and nuclei are labelled with Topro-3 Iodide (blue); 
x63/1.4. Raji cells were stained with CFSE (green) prior to incubation with Caco-2 cells. Raji cells were detectable below the 
inserts. 
3.2.2. Transport studies 
Transport studies were performed in order to compare the transport of free drug and LN containing ET in 
the Caco-2 monoculture and Caco-2/Raji co-culture. Integrity of the cell monolayer was evaluated by 
measuring TEER values before and after transport experiments. TEER values showed that LN did not 
alter tight junctions; in contrast, ET produced a significant decrease of the TEER if it is incubated for four 
hours. Fig. 6 shows the changes in TEER values after two hours of incubation with the different 
treatments. As can be observed, free ET was the only treatment that produced a decrease in the 
transepithelial resistance. Our results led us to conclude that transport experiments could not last for more 
than two hours due to the high disruption of the cell culture, measurable by the TEER value, which was 
caused by the free drug. Although LN were not harmful for the insert cultures over longer times, transport 




 Figure 6. Fold increase/decrease in TEER value of Caco-2 monolayer (left) and Caco-2/Raji co-culture (right) after 2 hours 
of incubation with the different treatments. Free drug was the only treatment that produced a slight decrease in TEER 
values. 
Rhodamine 123 and fluorescein were used as controls for the transport study. Rhodamine is a P-
glycoprotein (P-gp) substrate, a multidrug efflux transporter that avoids the absorption of potentially risk 
molecules in the intestine [23]. As ET is also a P-gp substrate [17], rhodamine 123 was used to assess the 
P-gp function in Caco-2 in vitro intestinal model in order to further evaluate P-gp efflux transporter. 
Rhodamine 123 transport is performed by paracellular transport from the apical side while it is 
internalized by the transcellular route and eluded to the apical side by the P-gp in case of secretory 
transport [24]. Fluorescein is transported via paracellular route and is a common marker used in transport 
studies to assess the integrity of the tight junctions. Due to its size, fluorescein presents very low 
permeability in Caco-2 monolayers because of the presence of tight junctions. Table 1 shows the apparent 
permeabilities (Papp) of both markers in the intestinal models studied.  Papp coefficients showed differences 
between the two culture models in case of secretory transport of rhodamine (from the basal to the apical 
compartment). As has been previously explained, the transport of both substances across Caco-2 
monolayer occurs via the paracellular route, which is consistent with the low Papp absorptive coefficients 
of fluorescein and rhodamine. It means that tight junctions between cells prevented the crossing of these 
molecules. Regarding the differences in rhodamine transport in each culture, rhodamine secretory 
transport (from the basolateral to the apical side) was about 11.5 (Caco-2 monoculture) and 2.2 (Caco-
2/Raji B co-culture) times higher than absorptive transport. This difference in transport rates has been 
previously described by other authors [24]. The difference in rhodamine secretory transport was clearer in 




Table 1. Apparent permeability coefficient (Papp x 10-6 (cm/s) of fluorescein and rhodamine in Caco-2 and Caco-2/Raji B 
cultures **p < 0.01; ***p < 0.001 vs. corresponding control group by two-way ANOVA (Bonferroni post-test). 
 Caco-2 monoculture Caco-2/Raji B co-culture 
Fluorescein 5.25 ± 0.10 6.05 ± 4.38 
Rhoamine 123 (Apical) 2.59 ± 0.26 9.04 ± 3.49 
Rhodamine 123 (Basal) 29.93 ± 2.15      *** 19.83±  0.53     ** 
 
LN have been shown to increase the oral bioavailability of many different drugs including ET [3], and 
therefore many researchers have shown an interest in in vitro models of the intestinal barrier that make it 
easier to assess the absorption of these nanosystems at the intestinal level [10, 25]. Roger et al. [25] 
studied the permeability of Paclitaxel across Caco-2 monolayers, concluding that LN were able to 
increase drug uptake up to 3.5 times. Beloqui et al. [10] also conclude that LN enhance the absorption of 
saquinavir; however, they report a lower drug permeability of LN across Caco-2/Raji B co-culture than in 
the enterocyte-like model. With these premises we expected to observe increased permeability of ET-LN 
compared to the free ET in the Caco-2 in vitro intestinal model. Fig. 7 shows the amount of drug after the 
experiment in each compartment (apical and basolateral sides and cells) at the end of the experiment (2 
hours). As can be observed, there was no ET in the basolateral side. This drawback did not allow us to 
calculate Paap of each treatment. Considering that only part of the ET quantity that decreases from the 
apical compartment is quantified inside the cells, ET might suffer some metabolic process inside Caco-2 
cells. ET is a synthetic PAF analog which contains a methyl group, attached by an ether linkage, at the sn-
2 position. This change in the molecule is related to a longer in vivo half-life because it prevents the 
degradation by the Phospholipase A2 (PLA2). However, ET is susceptible of being degraded by three 
pathways: i) cleavage of the alkyl group by glyceryl-ether monooxygenase (GEMO), ii) hydrolysis by 
Phospholipase C (PLC), and iii) Phospholipase D (PLD) hydrolysis [26]. Nowadays, ET degradation by 
GEMO has been discarded [26]. Wilcox et al [27] showed that ET is metabolized in MDCK, K-562 and 
HL-60 cells at very slow rates; however, hepatocytes metabolize up to half the administered ET after 24 
hours of incubation [28]. In conclusion, as has been demonstrated in hepatocytes, ET might be absorbed 
and metabolized in enterocytes. This process could be one of the causes of its poor oral bioavailability 
[2], and so the fate of ET in enterocytes should be further studied.  
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 Figure 7. Edelfosine (% of initial drug quantity on the donor compartment) present in the donor, acceptor and cell samples 
at the end of the transport experiment (2 hours of incubation) in Caco-2 monoculture (left) and Caco-2 co-culture (right). 
Free drug was not detectable in the basolateral chamber. It can also be observed that ET is internalized more rapidly than 
ET-LN in both culture models. 
Nevertheless, in spite of being unable to calculate Papp`s coefficients, we were able to compare the 
internalization rates of ET and ET-LN in both in vitro intestinal models. ET was internalized into the cells 
very quickly in both culture models; besides, its internalization was higher from the apical than from the 
basolateral side. This might be explained by the lipid nature of ET; actually, hydrophobic compounds are 
taken up more efficiently by Caco-2 cells than hydrophilic molecules [10, 29]. This could mean that the 
concentration of ET used in the transport studies is high enough to saturate the P-gp efflux system. This 
saturation process, dependent on the drug concentration, has been previously demonstrated with other 
drugs [30]. Besides, the apical enterocyte membrane is enriched with lipid rafts, microdomains enriched 
with cholesterol and glycolipids [31, 32] where ET accumulates in cells [33]. This high proportion of 
lipid rafts in the apical enterocyte membrane might also induce high absorption of the drug by the cells. 
Comparing both models, ET was internalized at a higher rate in both in vitro models: in fact, 76% and 
90.96% of LN remained in the apical side of Caco-2 monoculture and Caco-2/Raji co-culture respectively 
at the end of the transport experiment. These results are in agreement with results obtained by Roger et al. 
[25] who did not observe an increment in LN transport in the Caco-2/Raji B model in comparison with 
Caco-2 monoculture model. Taking into consideration that previous in vivo studies show an accumulation 
of drugs in the lymphatic system after their oral administration in LN [3], Caco-2/Raji co-culture might be 
not comparable to Peyer's patch follicle-associated epithelium (FAE) in the intestine. In this regard, the 
differentiation of induced pluripotent stem cells (iPS cells) into M cells [34, 35] has been documented. On 
the other hand, it seems clear the necessity of using bioreactors to achieve 3-D intestinal models [16]. In 
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this work, the authors state the formation of a more reliable 3D intestinal in vitro model when Caco2 cells 
are incubated with primary isolated human microvascular endothelial cells (hMECs) on decellularized 
porcine jejunal segments, within a custom-made dynamic bioreactor system. However, despite the 
successful obtained results, the early stage of development of these approaches entails disadvantages in 
comparison to the classic well-defined Caco-2 intestinal models. Therefore, efforts in research should be 
focused on the further development of these complex models with the aim of improving the in vitro 
testing of the intestinal absorption of drugs. 
4. Conclusions 
ET is internalized at a higher rate in its free form in both in vitro intestinal models (Caco-2 and Caco-
2/Raji). In fact, about 76% and 90% of the initial LN quantity remains in the donor compartment in Caco-
2 monoculture and Caco-2/Raji co-culture respectively after 2 hours of incubation These results do not 
correlate with those observed in vivo when ET-LN were administered orally in mice, which suggests that 
the microfold model is not a good model to study the absorption of ET-LN across the intestinal barrier in 
vitro. Indeed, our results suggest that ET might suffer some metabolic process upon being internalized in 
Caco-2 and Caco-2/Raji intestinal models. The absence of drug in the acceptor compartment and its poor 
oral bioavailability might be explained by a similar metabolic process in enterocytes. Finally, the rapid 
ET internalization in the culture monolayers (about 80% of the initial ET in two hours) might be related 
to the hydrophilic nature of the drug, the elevated presence of lipid rafts in the apical surface of 
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